Literature DB >> 15983901

Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity.

George S Deepe1.   

Abstract

Tumor necrosis factor (TNF)-alpha is required for host defenses against a number of pathogenic microbes, including Histoplasma capsulatum. In mice, TNF-alpha is necessary for the generation of a protective immune response to both primary and secondary histoplasmosis. Recent reports indicate that, in humans, treatment with inhibitors of TNF-alpha is associated with disseminated histoplasmosis. Here, I review the mechanisms by which inhibition of TNF-alpha may exacerbate infection with H. capsulatum.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15983901     DOI: 10.1086/429999

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  20 in total

1.  Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases.

Authors:  Paschalis Vergidis; Robin K Avery; L Joseph Wheat; Jennifer L Dotson; Maha A Assi; Smyrna A Antoun; Kassem A Hamoud; Steven D Burdette; Alison G Freifeld; David S McKinsey; Mary E Money; Thein Myint; David R Andes; Cynthia A Hoey; Daniel A Kaul; Jana K Dickter; David E Liebers; Rachel A Miller; William E Muth; Vidhya Prakash; Frederick T Steiner; Randall C Walker; Chadi A Hage
Journal:  Clin Infect Dis       Date:  2015-04-13       Impact factor: 9.079

Review 2.  Rheumatologic manifestations of histoplasmosis: a review.

Authors:  Travis C Sizemore
Journal:  Rheumatol Int       Date:  2013-07-09       Impact factor: 2.631

Review 3.  Serious infections with antirheumatic therapy: are biologicals worse?

Authors:  K L Winthrop
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 4.  [Risk of infection during treatment with tumor necrosis factor-alpha inhibitors].

Authors:  A Gaemperli; T Hauser; R Speck
Journal:  Z Rheumatol       Date:  2006-02       Impact factor: 1.372

5.  Characterization of the Histoplasma capsulatum-induced granuloma.

Authors:  Erika Heninger; Laura H Hogan; Jozsef Karman; Sinarack Macvilay; Bjork Hill; Jon P Woods; Matyas Sandor
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

6.  Conidia but not yeast cells of the fungal pathogen Histoplasma capsulatum trigger a type I interferon innate immune response in murine macrophages.

Authors:  Diane O Inglis; Charlotte A Berkes; Davina R Hocking Murray; Anita Sil
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

7.  Monoclonal antibodies to heat shock protein 60 alter the pathogenesis of Histoplasma capsulatum.

Authors:  Allan J Guimarães; Susana Frases; Francisco J Gomez; Rosely M Zancopé-Oliveira; Joshua D Nosanchuk
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

Review 8.  Histoplasma capsulatum at the host-pathogen interface.

Authors:  Joshua D Nosanchuk; Attila Gacser
Journal:  Microbes Infect       Date:  2008-07-10       Impact factor: 2.700

Review 9.  Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy.

Authors:  Jeannina A Smith; Carol A Kauffman
Journal:  Drugs       Date:  2009-07-30       Impact factor: 9.546

Review 10.  Histoplasma capsulatum surmounts obstacles to intracellular pathogenesis.

Authors:  Andrew L Garfoot; Chad A Rappleye
Journal:  FEBS J       Date:  2015-11-25       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.